Bone is permanently renewed by the coordinated actions of bone-resorbing osteoclasts and bone-forming osteoblasts, which model and remodel bone structure during growth and adult life. The origin of osteoblastic cells (osteoblasts, osteocytes and bone-lining cells) differs from that of osteoclasts, but both cell groups communicate with each other using cytokines and cell-cell contact as to optimally maintain bone homeostasis. This communication in many ways uses the same players as the communication between cells in the immune system. During acute life-threatening illness massive bone resorption is the rule, while bone formation is suppressed. During chronic illness, the balance between bone formation and bone resorption also shifts, frequently resulting in decreased bone mass and density. Several factors may contribute to the osteopenia that accompanies chronic illness, the most important being undernutrition and low body weight, inflammatory cytokines, disorders of the neuroendocrine axis (growth hormone/IGF-1 disturbances, thyroid and gonadal deficiency), immobilization, and the long-term use of glucocorticoids. Their combined effects not only influence the generation and activity of all bone cells involved, but probably also regulate their life span by apoptotic mechanisms. Osteopenia or even osteoporosis and bone fragility, and before puberty also decreased linear growth and lower peak bone mass are therefore frequent consequences of chronic illnesses.

Keywords:
Bone metabolism, Chronic illness
1.
Stein GS, Lian JB, Stein JL, Van Wijnen AJ, Montecino M: Transcriptional control of osteoblast growth and differentiation. Physiol Rev 1996;76:593–629.
2.
Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G: Osf2/Cbfa1:A transcriptional activator of osteoblast differentiation. Cell 1997;89:747–754.
3.
Ducy P, Starbuck M, Priemel M, Shen J, Pinero G, Geoffroy V, Amling M, Karsenty G: A Cbfα1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999;13:1025–1036.
4.
Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345–357.
5.
Hofbauer LC, Heufelder AE: The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000;85:2355–2363.
6.
Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN: The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000;133:795–799.
7.
Grinspoon S, Thomas E, Pitts S, Gross E, Mickley D, Miller K, Herzog D, Klibanski A: Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med 2000;133:790–794.
8.
Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, McClung M, Hosking D, Yates AJ, Christiansen C: Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 1999;14:1622–1627.
9.
Tremollieres FA, Pouilles JM, Ribot C: Vertebral postmenopausal bone loss is reduced in overweight women: A longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 1993;77:683–686.
10.
Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G: Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000;100:197–207.
11.
Woo PM: Growth retardation and osteoporosis in juvenile chronic arthritis. Clin Exp Rheumatol 1994;12(suppl 10):S87–S90.
12.
Chole RA: The molecular biology of bone resorption due to chronic otitis media. Ann NY Acad Sci 1997;830:95–109.
13.
Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, Nguyen T, Emery P: Osteoclastic activation is the principle mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998;7:1282–1289.
14.
Sugiyama T: Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis. J Bone Miner Metab 2001;19:89–96.
15.
Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689–1699.
16.
Zeitler PS, Travers S, Kappy MS: Advances in the recognition and treatment of endocrine complications in children with chronic illness. Adv Pediatr 1999;46:101–149.
17.
Wuster C, Rosen C Growth hormone, insulin-like growth factors: Potential applications and limitations in the management of osteoporosis; in Marcus R, Feldman D, Kelsey J (eds): Osteoporosis. San Diego, Academic Press, 2001, vol 2, pp 747–767.
18.
Baran D: Thyroid hormone and the skeleton; in Marcus R, Feldman D, Kelsey J (eds): Osteoporosis. San Diego, Academic Press, 2001, vol 2, pp 229–235.
19.
Schmid C, Schlapfer I, Futo E, Waldvogel M, Schwander J, Zapf J, Froesch ER: Triiodothyronine (T3) stimulates insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-2 production by rat osteoblasts in vitro. Acta Endocrinol (Copenh) 1992;126:467–473.
20.
Qin X, Gysin R, Mohan S, Baylink DJ: Bone growth factors; in Marcus R, Feldman D, Kelsey J (eds): Osteoporosis. San Diego, Academic Press, 2001, vol 1, pp 405–431.
21.
Gertner JM, Kaufman FR, Donfield SM, Sleeper LA, Shapiro AD, Howard C, Gomperts ED, Hilgartner MW: Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development Study. J Pediatr 1994;124:896–902.
22.
Sellmeyer DE, Grunfeld C: Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 1996;17:518–532.
23.
Leong GM, Center JR, Henderson NK, Eisman JA: Glucocorticoid-induced osteporosis: Basic pathological mechanisms, clinical features, and management in the new millennium; in Marcus R, Feldman D, Kelsey J (eds): Osteoporosis. San Diego, Academic Press, 2001, vol 2, pp 169–193.
24.
Horwood NJ, Elliott J, Martin TJ, Gillespie MT: Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998;139:4743–4746.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.